Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accounts Payables (2022 - 2025)

Historic Accounts Payables for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $16.3 million.

  • BioXcel Therapeutics' Accounts Payables rose 931.56% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year increase of 931.56%. This contributed to the annual value of $16.0 million for FY2024, which is 1710.85% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' Accounts Payables stood at $16.3 million, which was up 931.56% from $16.7 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Accounts Payables high stood at $17.2 million for Q1 2024, and its period low was $5.1 million during Q1 2022.
  • Moreover, its 4-year median value for Accounts Payables was $13.3 million (2024), whereas its average is $12.0 million.
  • In the last 5 years, BioXcel Therapeutics' Accounts Payables skyrocketed by 12242.31% in 2024 and then tumbled by 1027.87% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Accounts Payables stood at $10.2 million in 2022, then soared by 33.5% to $13.7 million in 2023, then grew by 17.11% to $16.0 million in 2024, then increased by 1.79% to $16.3 million in 2025.
  • Its Accounts Payables stands at $16.3 million for Q3 2025, versus $16.7 million for Q2 2025 and $15.4 million for Q1 2025.